Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Cymraeg
Cymraeg
Search
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE IDs
NICE IDs
30/01/2025
ID6405: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
16/09/2024
ID5088: Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria
12/09/2024
ID4042: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia
21/08/2024
ID6298: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
01/08/2024
ID6197: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
01/07/2024
ID6187: Relugolix for treating hormone-sensitive prostate cancer
31/05/2024
ID4025: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
24/04/2024
ID5104: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
21/02/2023
ID4038: Therapeutics for people with COVID-19
11/10/2021
ID1334: Glasdegib with chemotherapy for untreated acute myeloid leukaemia
11/10/2021
ID2710: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375)
11/10/2021
ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly
11/10/2021
ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma
11/10/2021
ID1631: Risdiplam for treating spinal muscular atrophy in children and adults
11/10/2021
ID1564: Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
11/10/2021
ID1609: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
11/10/2021
ID1604: Esketamine for treating major depressive disorder in adults at imminent risk for suicide
11/10/2021
ID1589: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
11/10/2021
ID945: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
11/10/2021
ID3787: Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis
1
2
3
4
5
6
7
8
Follow AWTTC: